Literature DB >> 20680813

Mesenchymal stem cell therapy for cardiac repair.

Andrew J Boyle1, Ian K McNiece, Joshua M Hare.   

Abstract

Stem cell therapy for repair of damaged cardiac tissue is an attractive option to improve the health of the growing number of heart failure patients. Mesenchymal stem cells (MSCs) possess unique properties that may make them a better option for cardiac repair than other cell types. Unlike other adult stem cells, they appear to escape allorecognition by the immune system and they have immune-modulating properties, thus making it possible to consider them for use as an allogeneic cell therapy product. There is a large and growing body of preclinical and early clinical experience with MSC therapy that shows great promise in realizing the potential of stem cell therapy to effect repair of damaged cardiac tissue. This review discusses the mechanism of action of MSC therapy and summarizes the current literature in the field.

Entities:  

Mesh:

Year:  2010        PMID: 20680813     DOI: 10.1007/978-1-60761-705-1_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  51 in total

Review 1.  Phenotyping patient-derived cells for translational studies in cardiovascular disease.

Authors:  Stanley Y Shaw; Ari D Brettman
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

Review 2.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 3.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

4.  The use of scaffold-free cell sheet technique to refine mesenchymal stromal cell-based therapy for heart failure.

Authors:  Takuya Narita; Yasunori Shintani; Chiho Ikebe; Masahiro Kaneko; Niall G Campbell; Steven R Coppen; Rakesh Uppal; Yoshiki Sawa; Kenta Yashiro; Ken Suzuki
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

Review 5.  Developmental origin and lineage plasticity of endogenous cardiac stem cells.

Authors:  Maria Paola Santini; Elvira Forte; Richard P Harvey; Jason C Kovacic
Journal:  Development       Date:  2016-04-15       Impact factor: 6.868

6.  Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction.

Authors:  P Locatelli; F D Olea; A Hnatiuk; A De Lorenzi; M Cerdá; C S Giménez; D Sepúlveda; R Laguens; A Crottogini
Journal:  Gene Ther       Date:  2015-03-19       Impact factor: 5.250

Review 7.  Copper promotion of myocardial regeneration.

Authors:  Ying Xiao; Tao Wang; Xin Song; Dan Yang; Qing Chu; Y James Kang
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-08

8.  Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells.

Authors:  Izuagie Attairu Ikhapoh; Christopher J Pelham; Devendra K Agrawal
Journal:  Differentiation       Date:  2015-04-23       Impact factor: 3.880

9.  TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC-mediated cardioprotection.

Authors:  Yue Wang; Aaron M Abarbanell; Jeremy L Herrmann; Brent R Weil; Mariuxi C Manukyan; Jeffrey A Poynter; Daniel R Meldrum
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

Review 10.  Therapeutic application of adipose derived stem cells in acute myocardial infarction: lessons from animal models.

Authors:  B A Naaijkens; A van Dijk; O Kamp; P A J Krijnen; H W M Niessen; L J M Juffermans
Journal:  Stem Cell Rev Rep       Date:  2014-06       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.